NCT00560066 - Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions | Biotech Hunter

Enrollment

1,398

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Seasonal InfluenzaVaccine

Interventions

BIOLOGICAL

Cell-derived influenza vaccine

1 dose of 0.5 mL in the deltoid region of the non-dominant arm

BIOLOGICAL

Egg-derived influenza vaccine

1 dose of 0.5 mL in the deltoid region of the non-dominant arm

Trial Locations (15)

Balve

Duisberg

Garmisch-Partenkirchen

Hanover

Herborn

Illingen

Kiel

Laufach

Marburg

Midlum

Olpe

Potsdam

Regensburg

Unterschleissheim

Wiesbaden